197 related articles for article (PubMed ID: 37138437)
21. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy.
Frati G; Schirone L; Chimenti I; Yee D; Biondi-Zoccai G; Volpe M; Sciarretta S
Cardiovasc Res; 2017 Mar; 113(4):378-388. PubMed ID: 28395009
[TBL] [Abstract][Full Text] [Related]
22. The Role of Renin-Angiotensin System in Diabetic Cardiomyopathy: A Narrative Review.
Batista JPT; Faria AOV; Ribeiro TFS; Simões E Silva AC
Life (Basel); 2023 Jul; 13(7):. PubMed ID: 37511973
[TBL] [Abstract][Full Text] [Related]
23. Diabetic Cardiomyopathy as a Clinical Entity: Is It a Myth?
Zaveri MP; Perry JC; Schuetz TM; Memon MD; Faiz S; Cancarevic I
Cureus; 2020 Oct; 12(10):e11100. PubMed ID: 33240696
[TBL] [Abstract][Full Text] [Related]
24. Novel dual glucagon-like peptide-1/ glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals.
Wang Y; Cai F; Li G; Tao Y
Bioengineered; 2022 Apr; 13(4):9184-9196. PubMed ID: 35383532
[TBL] [Abstract][Full Text] [Related]
25. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.
Wang L; Cai Y; Jian L; Cheung CW; Zhang L; Xia Z
Cardiovasc Diabetol; 2021 Jan; 20(1):2. PubMed ID: 33397369
[TBL] [Abstract][Full Text] [Related]
26. Role of inflammation in diabetic cardiomyopathy.
Ramesh P; Yeo JL; Brady EM; McCann GP
Ther Adv Endocrinol Metab; 2022; 13():20420188221083530. PubMed ID: 35308180
[TBL] [Abstract][Full Text] [Related]
27. Morphological characteristics in diabetic cardiomyopathy associated with autophagy.
Kanamori H; Naruse G; Yoshida A; Minatoguchi S; Watanabe T; Kawaguchi T; Tanaka T; Yamada Y; Takasugi H; Mikami A; Minatoguchi S; Miyazaki T; Okura H
J Cardiol; 2021 Jan; 77(1):30-40. PubMed ID: 32907780
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction, inflammation, oxidative stress, and fibrosis.
Rajesh M; Mukhopadhyay P; Bátkai S; Arif M; Varga ZV; Mátyás C; Paloczi J; Lehocki A; Haskó G; Pacher P
Geroscience; 2022 Jun; 44(3):1727-1741. PubMed ID: 35460032
[TBL] [Abstract][Full Text] [Related]
29. Medicinal chemistry of drugs used in diabetic cardiomyopathy.
Adeghate E; Kalasz H; Veress G; Teke K
Curr Med Chem; 2010; 17(6):517-51. PubMed ID: 20015035
[TBL] [Abstract][Full Text] [Related]
30. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.
Coccheri S
Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145
[TBL] [Abstract][Full Text] [Related]
31. Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies.
Tarquini R; Pala L; Brancati S; Vannini G; De Cosmo S; Mazzoccoli G; Rotella CM
Curr Med Chem; 2018; 25(13):1510-1524. PubMed ID: 28685679
[TBL] [Abstract][Full Text] [Related]
32. Diabetic cardiomyopathy: a clinical entity or a cluster of molecular heart changes?
Mizamtsidi M; Paschou SA; Grapsa J; Vryonidou A
Eur J Clin Invest; 2016 Nov; 46(11):947-953. PubMed ID: 27600276
[TBL] [Abstract][Full Text] [Related]
33. Endothelial Dysfunction and Diabetic Cardiomyopathy.
Wang M; Li Y; Li S; Lv J
Front Endocrinol (Lausanne); 2022; 13():851941. PubMed ID: 35464057
[TBL] [Abstract][Full Text] [Related]
34. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
[TBL] [Abstract][Full Text] [Related]
35. Diabetic cardiomyopathy: ongoing controversies in 2012.
Seferović PM; Milinković I; Ristić AD; Seferović Mitrović JP; Lalić K; Jotić A; Kanjuh V; Lalić N; Maisch B
Herz; 2012 Dec; 37(8):880-6. PubMed ID: 23223771
[TBL] [Abstract][Full Text] [Related]
36. Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat.
Tate M; Deo M; Cao AH; Hood SG; Huynh K; Kiriazis H; Du XJ; Julius TL; Figtree GA; Dusting GJ; Kaye DM; Ritchie RH
Diab Vasc Dis Res; 2017 Sep; 14(5):423-433. PubMed ID: 28565941
[TBL] [Abstract][Full Text] [Related]
37. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Joubert M; Jagu B; Montaigne D; Marechal X; Tesse A; Ayer A; Dollet L; Le May C; Toumaniantz G; Manrique A; Charpentier F; Staels B; Magré J; Cariou B; Prieur X
Diabetes; 2017 Apr; 66(4):1030-1040. PubMed ID: 28052965
[TBL] [Abstract][Full Text] [Related]
38. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.
Falcão-Pires I; Leite-Moreira AF
Heart Fail Rev; 2012 May; 17(3):325-44. PubMed ID: 21626163
[TBL] [Abstract][Full Text] [Related]
39. Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease.
Campbell DJ; Somaratne JB; Jenkins AJ; Prior DL; Yii M; Kenny JF; Newcomb AE; Schalkwijk CG; Black MJ; Kelly DJ
Cardiovasc Diabetol; 2011 Sep; 10():80. PubMed ID: 21929744
[TBL] [Abstract][Full Text] [Related]
40. [Diabetic cardiomyopathy: old disease or new entity?].
Seferović PM; Lalić NM; Seferović JP; Jotić A; Lalić K; Ristić AD; Simeunović D; Radovanović G; Vujisić-Tesić B; Ostajić MU
Srp Arh Celok Lek; 2007; 135(9-10):576-82. PubMed ID: 18088046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
